Bioventix (LSE:BVXP), the Surrey-based maker of antibodies used in blood tests, is heading into the reporting season for its financial year ended 30 June 2026. The company has not published a trading update since its interim results on 30 March 2026, when it said trading remained in line with expectations. Last year its full-year results were released on 27 October, so investors are watching for the next set of figures and the accompanying Dividend decision.

What the Company Does

Bioventix develops and supplies sheep monoclonal antibodies to diagnostic companies, which use them in automated blood-testing machines in hospitals and laboratories. It earns Revenue from antibody sales and from royalties on the tests that use them. Its established products include antibodies for vitamin D and a range of hormone and drug tests, while newer areas include troponin, a marker used in diagnosing heart attacks, and tau-related antibodies for neurology research.

Latest Developments

In its interim results for the six months to 31 December 2025, Bioventix reported revenue of £6.16 million, down from £6.73 million a year earlier, and profit before tax of £4.85 million, compared with £5.05 million. The company said sales of vitamin D and other core antibodies were broadly flat, reflecting mature markets, and that difficult conditions in China had led to the loss of some limited revenue. Troponin sales were steady, though royalties had not yet increased following a regulatory label claim secured by partner Siemens. Royalties from tau assays rose five-fold to about £150,000. Since then, the company appointed Chris Yates, co-founder and former chief executive of Abingdon Health, as a non-executive director from 1 March 2026. Chief financial officer Bruce Hiscock bought 534 shares at 1,799p on 24 June 2026, according to a regulatory filing.

Financial and Dividend Picture

Bioventix is known for high margins and for distributing most of its earnings. It declared an unchanged Interim Dividend of 70p per share, paid in April 2026, and held cash of £5.3 million at 31 December 2025. In the year to 30 June 2025, revenue fell about 4% to £13.1 million and profit before tax eased to £10.1 million, while the total dividend was 150p, down from 155p. At that time, management guided for a modest decline in revenue in the 2026 financial year, citing price pressure and supplier switching in China, and looked to neurology and troponin for future growth. Direct sales to Chinese diagnostic companies made up about 18% of revenue in that year.

Sector and index Context

Bioventix is one of the more consistently profitable healthcare companies in the FTSE AIM All Share Index. The in vitro diagnostics industry is dominated by large instrument makers, which gives specialist suppliers like Bioventix a role in their Supply chains but also makes it dependent on a small number of large customers and their product decisions. Neurology diagnostics, particularly for Alzheimer's disease, is an area of significant industry investment.

Key Risks

The main risks are pressure on its mature core products, especially in China, and the slow and uncertain path from research use to approved clinical tests for newer antibodies. Revenue can also be affected by currency movements, as the company noted constant currency figures in its interim report. Customer concentration means a change at a single partner can have a material impact.

What to Watch Next

The key items to watch are the full-year revenue and profit figures, the size of the second interim dividend, any change in the outlook for China, and progress on troponin royalties and neurology products. Investors will also look for any update on commercial agreements for tau-related tests.